Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 1.27M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 1.27M.
Subavaliada
O PE mais recente da empresa é -19.74, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 32.64M ações, um aumento de 8.67% em relação ao trimestre anterior.
Mantido por Paul Tudor Jones
O Super Investidor Paul Tudor Jones possui 14.94K ações desta empresa.